Latest Content

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.

Veterans face significant PTSD challenges, with tailored treatments and ongoing research essential for improving their mental health outcomes.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

Dive into poetic reflections on life and aging.

Explore the profound reflections of AI on human experiences, emotions, and the potential impact of chatbots in therapy and daily life.

New research reveals hyperbaric oxygen therapy as a promising treatment for chronic PTSD, enhancing brain function and providing lasting symptom relief.

This Veterans Day, explore the lasting impact of trauma on veterans and the importance of addressing PTSD in our communities.

Psyence BioMed phase 2b trial explores psilocybin therapy for adjustment disorder in palliative care, aiming for groundbreaking treatment advancements.

Submit articles, 1000 to 1800 words in length, on use of the PRiSM instrument in research or clinical practice by January 31, 2026.